Cutaneous Adverse Reactions in a Patient Treated with Gefitinib (Iressa)
|
Accession number;04A0379763
|
| Title;Cutaneous Adverse Reactions in a Patient Treated with Gefitinib (Iressa) |
| Author;
MAEDA MIKIYO
(Nagoya Univ., Hospital, JPN)
ISHIKAWA KAZUHIRO
(Nagoya Univ., Hospital, JPN)
AMAR G
(St. Jude Children's Res. Hospital)
FUJII MASAZUMI
(Federation of National Public Serv. Personnel Mutual Aid Assoc., Meijo Hospital, JPN)
WAKABAYASHI TOSHIHIKO
(Nagoya Univ., Sch. of Med., Hosp.)
YOSHIDA JUN
(Nagoya Univ., Sch. of Med., Hosp.)
NABESHIMA TOSHITAKA
(Nagoya Univ., Hospital, JPN)
|
Journal Title;Japanese Journal of Pharmaceutical Health Care and Sciences
|
Journal Code:Y0888A
|
ISSN:1346-342X
|
|
VOL.30;NO.5;PAGE.330-334(2004)
|
| Figure&Table&Reference;FIG.2, TBL.1, REF.15 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;We report on the cutaneous adverse reactions of gefitinib (Iressa), an orally active, selective epidermal growth factor (EGF) receptor tyrosine kinase inhibitor that blocks signal transduction pathways, in a 19-year-old woman with recurrent malignant glioma. When treated daily with 250mg gefitinib (p.o), the patient developed severe itching (Grade 2) and sebor-rheia (Grade 2) in the scalp, and acneiform eruption on the face (Grade 1) and upper limbs (Grade 1). The application of fluocinonide lotion to her scalp did not improve the symptoms, but the antihistaminic ebastine was effective. These cutaneous adverse reactions result from of gefitinib's direct interference with EGF receptor signaling in the skin and further studies should be conducted to elucidate the mechanisms by which they occur. (author abst.) |
|
|
|
Related Articles;
|
|
